BCAL Diagnostics

BCAL Diagnostics EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of BCAL Diagnostics (BDX.AX) as of Oct 17, 2026 is -6.06 M AUD. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was -5.60 M AUD — a change of 8.36% (lower).

EBITDA

-6.06 MAUD

YoY

8.36%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of BCAL Diagnostics is 2025 -6.06 M AUD. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of BCAL Diagnostics was 2024 -5.60 M AUD. It decreases by 8.36% lower compared to the previous year.

The BCAL Diagnostics EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2018
-449,100.00 AUD
Jan 1, 2019
-423,000.00 AUD
Jan 1, 2020
-689,200.00 AUD
Jan 1, 2021
-935,200.00 AUD
Jan 1, 2022
-3.19 M AUD
Jan 1, 2023
-4.89 M AUD
Jan 1, 2024
-5.60 M AUD
Jan 1, 2025
-6.06 M AUD
The BCAL Diagnostics EBITDA history
YEAREBITDAYoY
-6.06 MAUD+8.36%
-5.60 MAUD+14.37%
-4.89 MAUD+53.17%
-3.19 MAUD+241.52%
-935,200.00AUD+35.69%
-689,200.00AUD+62.93%
-423,000.00AUD-5.81%
-449,100.00AUD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

BCAL Diagnostics Stock analysis

What does BCAL Diagnostics do? BCAL Diagnostics Ltd, based in Sydney, Australia, operates in the Health Care sector within the Biotechnology industry. The company develops innovative blood screening tests for early breast cancer detection, focusing on a lipid biomarker-based approach known as the BCAL test. This technology complements existing imaging methods like mammograms and aims to support screening and monitoring for women of all ages and backgrounds. BCAL Diagnostics has partnered with Precion Inc. to advance clinical trials and regulatory approvals for its diagnostic solutions. BCAL Diagnostics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BCAL Diagnostics stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of BCAL Diagnostics is -6.06 M AUD in 2025.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of BCAL Diagnostics changed from -5.60 M AUD to -6.06 M AUD, representing a 8.36% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) BCAL Diagnostics since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s AUD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s BCAL Diagnostics historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — BCAL Diagnostics

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — BCAL Diagnostics